Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ploegsteert – page 10

1 758 clinical trials in Ploegsteert, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ploegsteert at a glance
1 758
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 758 trials in Ploegsteert

Open in trial search

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Recordati AG

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase II study of fixed‑dose, accelerated ramp‑up epcoritamab plus lenalidomide in patients with relapsed/refractory large B‑cell lymphoma after CAR‑T therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Efficacy and Safety of BAY 3670549 in Adults with Atrial Fibrillation: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2 Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3670549
  • Sponsor:Bayer AG

Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AZD8965
  • Sponsor:AstraZeneca AB

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ploegsteert

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) management strategies in primary care settings, examining optimal approaches for medication reduction in patients with chronic usage patterns.

  • Functional Dyspepsia
  • Gastroesophageal Reflux
  • Chronic Heartburn Management

The research explores alternative treatment approaches, including on-demand medication use and alginate-based therapy, comparing their effectiveness to traditional deprescribing methods.

02 Primary Care Innovation

Studies evaluating strategic approaches to medication optimization in primary care, with a focus on reducing long-term dependency on acid-suppressing medications.

  • Medication Deprescribing
  • Patient-Centered Care
  • Treatment Optimization

This research aims to establish evidence-based guidelines for managing chronic medication use while maintaining therapeutic effectiveness.

03 Therapeutic Management

Investigation into alternative treatment strategies for common gastrointestinal conditions, focusing on comparative effectiveness of different therapeutic approaches.

  • Medication Management
  • Treatment Alternatives
  • Clinical Outcomes

The research evaluates various therapeutic options to identify optimal treatment pathways for patients requiring long-term acid suppression therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.